No human safety data supports GLP-1 use during pregnancy, and animal studies show fetal skeletal abnormalities at high doses
Microdosing GLP-1 for Autoimmune Conditions According to a comprehensive systematic review published in 2024, treatment with GLP-1 receptor agonists results in significant reductions in disease severity among patients with psoriasis
In DCCT, participants were randomised to either intensive or conventional insulin therapy (achieving a median HbA 1c level of 7% vs 9% [53 vs 75 mmol/mol], respectively) and followed for a mean of 6.5 years
Researchers also examined major adverse CV events in patient subgroups on the basis of major adverse CV event rates in the placebo group, the presence or absence of CVD, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age and eGFR
Start with 10-15 minutes of walking twice daily
Its ability to slow down food movement through the stomach contributes to a prolonged feeling of fullness, aiding individuals in curbing their appetite and regulating food intake
